TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06082635 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

321

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: TGRX-326
DRUG: Crizotinib

Sponsor

Shenzhen TargetRx Co., Ltd.

Collaborators

[object Object]